Sino Biopharmaceutical announces LM-350 a CDH17 ADC has received the IND approval from NMPA

CAR-T Digest - August 2020

18 November 2025: Sino Biopharmaceutical announces LM-350, a CDH17 ADC has received the IND approval from NMPA

Sino Biopharmaceutical announced that its subsidiary LaNova Medicines received NMPA approval in China to begin clinical trials for LM-350, a CDH17-targeting ADC developed using the next-generation LM-ADC platform
LM-350 shows high selectivity for CDH17, strong internalization, wild-type IgG1 configuration, and ADCC activity, supporting its therapeutic potential
Preclinical studies demonstrated significant anti-tumor activity across multiple xenograft models, especially in colorectal cancer models resistant to MMAE or irinotecan
CDH17 is highly expressed in major gastrointestinal cancers including colon, gastric, esophageal, and pancreatic tumors areas with high global incidence and substantial unmet clinical need
LM-350 previously received FDA IND approval and dosed its first patient in Australia in September 2025, the new China approval will accelerate its clinical development with the aim of offering a novel treatment option to patients